Program Overview
Bring your entire promotional review team to this year's Marketing Pharmaceuticals 2012.
It's not getting any easier to understand or be in compliance with all the various regulatory and legal requirements that apply to Rx and OTC drug and device promotional materials. The Food and Drug Administration and Office of Inspector General/Department of Justice continue to take enforcement actions. In addition, there are many voluntary codes and other standards that companies must adapt to their own products. The penalties for non-compliance go beyond an FDA warning letter. The substantial fines, criminal and civil legal actions and corporate integrity agreements affect how every company and vendor does business.
Don't be caught unprepared. Bring your entire promotional review team to this year's Marketing Pharmaceuticals 2012, where, in just 2 days, you will:
- Gain a better understanding of how the regulatory and legal environment has evolved and affects the marketing and promotion of pharmaceuticals, biologics, and medical devices
- Receive practical, day-to-day guidance based from the latest FDA enforcement actions, as well as federal and state civil and criminal actions and settlements
- Learn about FDA guidance documents and policies currently in development or being considered
- Hear about the latest enforcement activities by the centers within FDA that regulate medical marketing: drugs (CDER), biological products (CBER), and medical devices (CDRH)
- Be informed on what's new in Medical Policy Initiatives
- Obtain information about Substantial Evidence and other Standards
- Discuss considerations in a Multimedia World
- Attend breakout sessions designed for each member of your promotional review team to help foster a common understanding of how marketing is conducted in a highly regulated environment
Learning Objectives
At the conclusion of this meeting, participants should be able to:
- Identify the trends reflected in the latest enforcement actions and policies issued by the FDA
- Explain how to work collaboratively with those who review promotional materials
- Recognize best practices in complying with regulatory policies
- Outline the policies and actions being taken by OIG, DOJ and local states regarding medical marketing noncompliance
- Describe how to market products while complying with the FDA and other policies and regulations
Who Should Attend
Professionals in pharmaceutical, biologics, and medical device companies involved in:
- Marketing
- Marketing Communications
- Legal/Regulatory Affairs
- Public Relations/Corporate Affairs
- Medical Information and Affairs
- Advertising Agencies
- Compliance
- Senior Management
Event Information
Contact Joanne Wallace, Program Manager
Phone: 1-215-442-6180 Fax: 1-215-442-6199 email: Joanne.Wallace@diahome.org
Special thanks to our media partner:
Program Committee
Thomas W. Abrams, MBA, RPh
Director, Office of Prescription Drug Promotion (OPDP)
CDER, FDA
Glenn N. Byrd, MBA, RAC
Senior Director, Regulatory Affairs
MedImmune, LLC
Mark Gaydos
Vice President
US Regulatory Affairs Marketed Products
sanofi–aventis U.S.
John T. Murray
President, Grayscale Compliance LLC
Wayne L. Pines
President, Regulatory Services and Healthcare
APCO Worldwide, Inc.
Lucy Rose, MBA
President
Lucy Rose and Associates, LLC
Kristina Spranger, MPH
Director, Regulatory Promotions
Amgen Inc.
Continuing Education
Continuing Education Credits
The Drug Information Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy
education. The tutorial and program are designated for up to 15.25 contact hours or 1.525 continuing education units (CEUs).
Type of Activity: Knowledge
Drug Information Association has been approved as an Authorized Provider by the International Association for Continuing Education and
Training (IACET), 8405 Greensboro Drive, Suite 800, McLean, VA 22102 (703) 506-3275.
Drug Information Association is authorized by IACET to offer 1.5 CEUs for the tutorial and program. Participants must attend the entire program and tutorial to be eligible to receive a IACET statement of credit. No partial credit will be awarded.
If you would like to receive a statement of credit, you must attend the program (and tutorial if applicable), scan your name badge at the tutorial, on Day 1 of the program, and at each session you attend on Day 2, and complete the on-line credit request process through My Transcript at www.diahome.org. Participants will be able to download a statement of credit upon successful submission of the credit request. My Transcript will be available for credit requests on March 2, 2012.
Continuing Education Credit Allocation
Tutorial
Pharmacy - 286-000-12-036-L04-P, 3.25 contact hours or .325 CEUs
IACET - .3 CEUs
Program
Pharmacy:
- Day 1: Sessions 1-4 – 286-000-12-037-L04-P, 6.75 contact hours or .675 CEUs
- Day 2: Session 5:
- Interactive Session 1 – 286-000-12-038-L04-P, 1.25 contact hours or .125 CEUs
- Interactive Session 2 – 286-000-12-039-L04-P, 1.25 contact hours or .125 CEUs
- Interactive Session 3 – 286-000-12-040-L04-P, 1.25 contact hours or .125 CEUs
- Day 2: Session 6:
- Interactive Session 1 – 286-000-12-038-L04-P, 1.25 contact hours or .125 CEUs
- Interactive Session 2 – 286-000-12-039-L04-P, 1.25 contact hours or .125 CEUs
- Interactive Session 3 – 286-000-12-040-L04-P, 1.25 contact hours or .125 CEUs
- Day 2: Session 7 – 286-000-12-041-L04-P, 1.5 contact hours or .15 CEUs
- Day 2: Session 8 – 286-000-12-042-L04-P, 1.25 contact hours or .125 CEUs
IACET – 1.2 CEUs
Disclosure Policy
It is Drug Information Association policy that anyone in a position to control the content of a continuing education activity must disclose to the program audience (1) any real or apparent
conflict(s) of interest related to the content of their presentation and/or the educational activity, and (2) discussions of unlabeled or unapproved uses of drugs or medical devices. Faculty disclosures will be included in the course materials.
Program Agenda
Tutorial Day | February 15
12:30-1:30 PM Tutorial Registration
1:30-5:30 PM OPDP/APLB and Compliance 101: A Primer
Instructors
Lucy Rose, MBA
President, Lucy Rose and Associates, LLC
Paul J. Savidge, JD, MBA
Vice President & Associate General Counsel,
Regulatory/Commercial Law
Bristol-Myers Squibb Co.
Michele Sharp, PharmD
Senior Director, Global Regulatory Affairs - US
Eli Lilly and Company
If you are new, or relatively new, to DDMAC and/or advertising/promotional compliance, this tutorial is for you!! The leaders will provide a strong introductory foundation for anyone working in our new regulatory environment. Whether you are a regulatory, legal, medical, or marketing professional, the information will be interesting, practical and vital!
Tutorial Learning Objectives
At the conclusion of this tutorial, participants should be able to:
- Discuss the current regulatory/compliance environment pertaining to prescription drugs, biologics and medical devices, both from an FDA and OIG/DOJ perspective
- Describe the FDA advertising and promotional requirements, including such topics as: claim support requirements, fair balance expectations, internet challenges, product booths at medical conventions, disease state programs, and public relations challenges.
Tutorial Target Audience
This program is designed for individuals involved in marketing, legal, regulatory, public affairs, and advertising in the pharmaceutical and biologics industries, plus their consultants and agencies. If you are relatively new to this area, please join our experienced experts to gain the important information you need to maximize your conference learning!
Conference Day 1 | Thursday, February 16
7:00-8:30 AMRegistration and Continental Breakfast
8:30-8:35 AMWELCOME AND OPENING REMARKS
Wayne L. Pines
President, Regulatory Services and Healthcare
APCO Worldwide, Inc.
8:35-10:00 AM Session 1
FDA Update: Recent Enforcement Actions
Session Chairperson:
Wayne L. Pines
President, Regulatory Services and Healthcare
APCO Worldwide, Inc.
This session provides an overview of current issues, laws and regulations relevant to the promotion of prescription drugs, biologics and medical devices. Learn the latest on policy development, enforcement and FDA's future initiatives.
CDER Update
Thomas W. Abrams, MBA, RPh
Director, Office of Prescription Drug Promotion (OPDP)
CDER, FDA
CBER Update
Loan Nguyen, PharmD
Regulatory Review Officer
Advertising Promotional and Labeling Branch (APLB),
CBER, FDA
Alpita Popat, PharmD, MBA
Consumer Safety Officer
Advertising Promotional and Labeling Branch (APLB),
CBER, FDA
CDRH Update
Toni M. Stifano
Consumer Safety Officer, OC
CDRH, FDA
10:00-10:30 AM Refreshment Break
10:30-11:45 AM Session 2
Meeting the Federal and State Requirements for Appropriate Marketing Practices: Update
Session Chairperson:
John Patrick Oroho, JD
Principal, Porzio Bromberg & Newman P.C. and
Executive Vice President and Chief Strategy Officer,
Porzio Pharmaceutical Services, LLC
This session will provide an update on the latest state and federal legislation and court decisions that affect drug and device marketing. Included will be a discussion of sunshine laws and relevant court decisions and corporate integrity agreements.
Speakers:
Jennifer A. Sanfilippo, JD
Director, Global Contracting and Business Ethics
The Medicines Company
Elizabeth H. Kim, JD
Associate at Porzio, Bromberg & Newman, PD
Manager of Regulatory and Compliance at
Porzio Pharmaceutical Services, LLC
11:45 AM-1:15 PM Luncheon
What's New in Medical Policy Initiatives
Luncheon Speaker
Kathleen Uhl, MD
Deputy Director, Office of Medical Policy, CDER, FDA
1:15-2:45 PM Session 3
Substantial Evidence and other Standards
Session Chairperson
Glenn N. Byrd, MBA, RAC
Senior Director, Regulatory Affairs
MedImmune, Inc.
The quality/type of data needed to support various claims depends upon the type of claims one is seeking, such as treatment benefit claims (e.g., clinical outcomes, patient-reported outcomes) and non-clinical claims (e.g., convenience, ease of use), to cite a few. This area is a source of frequent disagreement between regulatory/legal reviewers and marketing teams. It is also a topic frequently cited by FDA in their enforcement actions.
This session will explore the meaning of terms such as: substantial evidence, substantial clinical experience; adequate evidence, competent and reliable evidence, etc.; and examine related enforcement actions.
Elaine Hu Cunningham, PharmD
Senior Regulatory Review Officer, Evidence Review,
Office of Prescription Drug Promotion, CDER/FDA
Mark S. Hirsch, M.D.
Medical Team Leader
Division of Reproductive and Urologic Products, Office of Drug
Evaluation 3
OND, CDER/FDA
Paivi H. Miskala, MSPH, PhD
Study Endpoints Reviewer,
Study Endpoints and Labeling Development
Office of New Drugs, CDER/FDA
Paul J. Savidge, JD, MBA
Vice President & Associate General Counsel,
Regulatory/Commercial Law
Bristol-Myers Squibb Co.
2:45-3:15 PM Refreshment Break
3:15-4:45 PM Session 4
Considerations in a Multi-Media World
Session Chairperson
Kristina Spranger, MPH
Director, Regulatory Promotions
Amgen Inc.
This session will provide an overview of regulatory considerations for the ever-evolving arena of multi-media tools. Additionally, the session includes presentations of exciting tools and programs which are being supported, developed or considered by many of your colleagues.
The Multi-media Landscape: The New Frontier
Dale A. Cooke
Vice President/Group Director, Regulatory Review
Digitas Health & Razorfish Health
Peer to Peer Mentoring & Patient Networking: The Power of Connecting
David Gusdorf
Vice President
Health Advocacy Strategies, LLC
Regulatory Principles and Their Application to the Rapidly Evolving Multi-Media World
Lynette Hopkinson
Director, Commercial Regulatory Affairs
Eisai, Inc.
4:45-5:45 PM Reception
Conference Day 2 | Friday, February 17
7:30-8:30 AM Registration and Continental Breakfast
8:30-11:30 AM Interactive Sessions
Interactive sessions offer attendees day-to-day practicalities in an interactive/ hands-on/role-playing environment using case studies and simulation with information that can be taken back to the office and shared with colleagues. These sessions will offer the opportunity for companies to send all members of their "Promotional Review Teams" to enable them to work more cohesively together and with FDA (and other agencies).
8:30-9:45 AM Session 5: Ineractive Sessions
Interactive Session 1
FDA MA 114 and FDA Regulation of Health Care Economic Information (HCEI)
This workshop will focus on the continued use of cost and health care economic information by drug and biologic manufacturers and the challenges of evaluating its compliance with FDA regulations. The FDA Modernization Act of 1997 (FDAMA) contains limited guidance on the dissemination of health care economic analyses by drug and biologic manufacturers (FDAMA Section 114). The growing need by private and government payers to control medical costs leads to a continuously growing demand for data to support drug costs, including government sponsored comparative effectiveness research. This panel will explore these issues and the challenges FDA regulated companies face when communicating HCEI.
- What is health care economic information (HCEI), who uses it, and how is it used?
- What do companies need to do to assure they are in compliance with FDA regulations and FDAMA Section 114?
- What constitutes competent and reliable evidence and how has FDA enforced against inappropriate health economic promotion?
- How is the landscape changing for private and government creation and use of HCEI and how might this affect how HCEI is used in promotion?
Moderator:
John T. Murray
President, Grayscale Compliance LLC
Panelists:
Brian Ortmeier, PharmD, PhD
Therapeutic Area Lead
Inflammation Global Health Economics
Amgen Inc.
Meredith Manning, JD, MS
Partner,
Hogan Lovells US LLP
Tracy Acker, PharmD
Principal, The Acker Group, LLC
Una Ortell, MSc
Director Regulatory Affairs Promotion
and Advertising
Takeda Global Research
and Development Center Inc
Interactive Session 2
Building Compliant Global Marketing Campaigns
Companies are increasingly looking for consistency in marketing campaigns across the globe. This raises challenges for the Ad Promo review process in determining appropriate company review standards and finding efficient ways to achieve regulatory approval of promotional materials. This session will discuss:
- How to remain compliant in the International Marketing Arena
- Major differences in Country Codes
- Core Promotional Materials
- Basic Safety Information
- Interpretation of Clinical Data
- Local Customization within Markets
- Avoiding the "lowest common denominator"
Moderator:
Tom Casola, MBA
Vice President, Global Regulatory Affairs,
Advertising, Promotion & Labeling
Shire Specialty Pharmaceuticals
Panelists:
Sandra Kerr, RPh
Head, Office of Promotion and Advertising Review
Merck & Co., Inc
Jeffrey K. Francer, JD, MPP
Assistant General Counsel
PhRMA
José F. Zamarriego Izquierdo, PhD
Director of Code of Practice
Surveillance Unit, FARMAINDUSTRIA
Arturo Lopez-Gil, MD, PhD
Clin Pharm Specialist
Senior Director Global Regulatory Affairs
Shire AG, Nyon Switzerland
Heather Simmonds
Director
Prescription Medicines Code of Practice Authority (PMCPA)
Interactive Session 3
Updates from the Exhibit Hall Floor: The Changing Medical Convention Landscape
In this session, regulatory and legal experts will examine the evolving presence of pharmaceutical and medical device companies at medical conventions. Among other topics, they will discuss:
- Product promotion in the post-PhRMA Code era
- Presenting company research activities
- International booths
- Staffing issues
- Recent enforcement actions
Moderator:
Mark Gaydos
Vice President
US Regulatory Affairs Marketed
Products
sanofi–aventis U.S.
Panelists:
Alan G. Minsk
Partner and Leader, Food and Drug
Practice Team
Arnall Golden Gregory LLP
Cynthia Phillips, MBA
Senior Director Regulatory Global
Labeling and Promotion
Millennium Pharmaceuticals
John Weindenbruch
Vice President, Chief Commercial Council
Biogen Idec
9:45-10:15 AM Refreshment Break
10:15-11:30 AM Session 6: Interactive Sessions (Repeated)
Interactive Session 1
FDA MA 114 and FDA Regulation of Health Care Economic Information (HCEI)
This workshop will focus on the continued use of cost and health care economic information by drug and biologic manufacturers and the challenges of evaluating its compliance with FDA regulations. The FDA Modernization Act of 1997 (FDAMA) contains limited guidance on the dissemination of health care economic analyses by drug and biologic manufacturers (FDAMA Section 114). The growing need by private and government payers to control medical costs leads to a continuously growing demand for data to support drug costs, including government sponsored comparative effectiveness research. This panel will explore these issues and the challenges FDA regulated companies face when communicating HCEI.
- What is health care economic information (HCEI), who uses it, and how is it used?
- What do companies need to do to assure they are in compliance with FDA regulations and FDAMA Section 114?
- What constitutes competent and reliable evidence and how has FDA enforced against inappropriate health economic promotion?
- How is the landscape changing for private and government creation and use of HCEI and how might this affect how HCEI is used in promotion?
Moderator:
John T. Murray
President, Grayscale Compliance LLC
Panelists:
Brian Ortmeier, PharmD, PhD
Therapeutic Area Lead
Inflammation Global Health Economics
Amgen Inc.
Meredith Manning, JD, MS
Partner,
Hogan Lovells US LLP
Tracy Acker, PharmD
Principal, The Acker Group, LLC
Una Ortell, MSc
Director Regulatory Affairs Promotion
and Advertising
Takeda Global Research
and Development Center Inc
Interactive Session 2
Building Compliant Global Marketing Campaigns
Companies are increasingly looking for consistency in marketing campaigns across the globe. This raises challenges for the Ad Promo review process in determining appropriate company review standards and finding efficient ways to achieve regulatory approval of promotional materials. This session will discuss:
- How to remain compliant in the International Marketing Arena
- Major differences in Country Codes
- Core Promotional Materials
- Basic Safety Information
- Interpretation of Clinical Data
- Local Customization within Markets
- Avoiding the "lowest common denominator"
Moderator:
Tom Casola, MBA
Vice President, Global Regulatory Affairs,
Advertising, Promotion & Labeling
Shire Specialty Pharmaceuticals
Panelists:
Sandra Kerr, RPh
Head, Office of Promotion and Advertising Review,
Merck & Co., Inc
Jeffrey K. Francer, JD, MPP
Assistant General Counsel
PhRMA
José F. Zamarriego Izquierdo, PhD
Director of Code of Practice
Surveillance Unit, FARMAINDUSTRIA
Arturo Lopez-Gil, MD, PhD
Clin Pharm specialist
Senior Director Global Regulatory Affairs
Shire AG, Nyon Switzerland
Heather Simmonds
Director
Prescription Medicines Code of Practice Authority (PMCPA)
Interactive Session 3
Updates from the Exhibit Hall Floor: The Changing Medical Convention Landscape
In this session, regulatory and legal experts will examine the evolving presence of pharmaceutical and medical device companies at medical conventions. Among other topics, they will discuss:
- Product promotion in the post-PhRMA Code era
- Presenting company research activities
- International booths
- Staffing issues
- Recent enforcement actions
Moderator:
Mark Gaydos
Vice President
US Regulatory Affairs Marketed
Products
sanofi–aventis U.S.
Panelists:
Alan G. Minsk
Partner and Leader, Food and Drug
Practice Team
Arnall Golden Gregory LLP
Cynthia Phillips, MBA
Senior Director Regulatory Global
Labeling and Promotion
Millennium Pharmaceuticals
11:30-1:00 PM Luncheon
Recent Court Cases
Luncheon Speaker
Alan R. Bennett, JD
Partner, Ropes & Gray
1:00-2:20 PM Session 7
Electronic Submissions of Promotional Materials:
Draft Update to Module 1
Session Chairperson
Marci Kiester, PharmD
Associate Director, Office of Prescription Drug Promotion
CDER, FDA
This session will focus on the draft FDA updates to the eCTD Module 1 specifications. The session will include an overview of proposed changes to Module 1, discussion of current submission processes, and FDA's implementation plans for the future release of the Module 1 update.
Marci Kiester, PharmD
Associate Director, Office of Prescription Drug Promotion
CDER, FDA
Lisa M. Hubbard, RPh
Group Leader, Division of Professional Promotion
Office of Prescription Drug Promotion, CDER, FDA
Michael Brony, PharmD
Regulatory Review Officer, APLB
CBER, FDA
2:20-2:35 PM Refreshment Break
2:35-3:05 PM Session 8
FDA Draft Guidance for Industry: Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices
Session Chairperson
Jean-Ah Kang, PharmD
Special Assistant to the Director
Office of Prescription Drug Promotion (OPDP)
FDA
This session provides an overview of this draft guidance on FDA's current views and how manufacturers and distributors (Firms) of prescription human and animal drug products and medical devices can respond to unsolicited requests for information about unapproved or uncleared indications or conditions of use (off-label information) related to their FDA-approved or cleared products, including those that firms may encounter through emergency electronic media.
3:05- 4:15 PM Session 9
Question and Answer Session with FDA
Session Chairperson
Lucy Rose, MBA
President
Lucy Rose and Associates, LLC
Use this unique opportunity to bring your pressing questions for FDA to address in person. This session will attempt to answer any remaining questions from earlier sessions and to allow the audience to ask new questions to our FDA speakers.
CDER
Thomas W. Abrams, MBA, RPh
Director, Office of Prescription Drug Promotion (OPDP)
CDER, FDA
CBER
Lisa L. Stockbridge, PhD
Branch Chief, Advertising and Promotional Labeling Branch,
CBER, FDA
CDRH
Terri T. Garvin
Regulatory Counsel
PAPS/OC/CDRH/FDA
Deborah Wolf, JD
Regulatory Counsel, Office of Compliance
CDRH, FDA
OPDP
Jean-Ah Kang, PharmD
Special Assistant to the Director
Office of Prescription Drug Promotion (OPDP)
FDA
4:15 PM Conference Adjourned
Unless otherwise disclosed, the statements made by speakers represent their own opinions and not necessarily those of the organization they represent, or that of the DIA.
Speakers, agenda, and CE information are subject to change without notice.
Recording of any DIA educational material in any type of media, is prohibited without prior written consent from DIA.
To view DIA's Grievance Policy, please visit the CE page on DIA's website at www.diahome.org.
Tutorial Information
Tutorial: OPDP/APLB and Compliance 101: A Primer
Date & Time:
Wednesday, Feb 15 2012 1:30PM - 5:00PM
Instructor(s):
Lucy Rose, MBA
President, Lucy Rose and Associates, LLC
Paul J. Savidge, JD, MBA
Vice President & Associate General Counsel,
Regulatory/Commercial Law
Bristol-Myers Squibb Co.
Michele Sharp, PharmD
Senior Director, Global Regulatory Affairs - US
Eli Lilly and Company
Description
If you are new, or relatively new, to DDMAC and/or advertising/promotional compliance, this tutorial is for you!! The leaders will provide a strong introductory foundation for anyone working in our new regulatory environment. Whether you are a regulatory, legal, medical, or marketing professional, the information will be interesting, practical and vital!
Tutorial Learning Objectives
At the conclusion of this tutorial, participants should be able to:
- Discuss the current regulatory/compliance environment pertaining to prescription drugs, biologics and medical devices, both from an FDA and OIG/DOJ perspective
- Describe the FDA advertising and promotional requirements, including such topics as: claim support requirements, fair balance expectations, internet challenges, product booths at medical conventions, disease state programs, and public relations challenges.
Tutorial Target Audience
This program is designed for individuals involved in marketing, legal, regulatory, public affairs, and advertising executives in the pharmaceutical and biologics industries, plus their consultants and agencies. If you are relatively new to this area, please join our experienced experts to gain the important information you need to maximize your conference learning!
Registration & Travel
Registration Fees
If DIA cannot verify your membership, you will be charged the nonmember fee. Registration fee includes refreshment breaks, luncheons, and reception (if applicable), and will be accepted by mail, fax, or online.
| Member Early-bird Opportunity Available on nondiscount member fee only |
On or before Jan. 25, 2012 |
After Jan. 25, 2012 |
| Member Fee | US $1340 | US $1490 |
| Join DIA now to qualify for the early-bird member fee! | Membership | |
| US $140 | ||
| To qualify for the early-bird discount, registration form and accompanying payment must be received by the date above. Does not apply to government/academia/nonprofit members. | ||
| Nonmember Fee | US $1630 | |
| A one-year membership to DIA is available to those paying a nonmember registration fee. If paying a nonmember fee, please indicate if you do, or do not, want membership. | ||
| Discount Fees | Member | Non-Member |
| Government (Full-time) | US $595 | US $735 |
| Charitable Nonprofit/Academia (Full-time) | US $745 | US $885 |
| Tutorial: OPDP/APLB and Compliance 101: A Primer Wednesday, February 15, 2012 - 1:30-5:00 PM |
US $450 | |
Group Discounts:
Register three individuals from the same company and receive complimentary registration for a 4th! All 4 individuals must register and prepay at the same time – no exceptions. DIA will apply the value of the lowest applicable fee to this complimentary registration; it does NOT include fees for optional events or DIA membership. You may substitute group participants of the same membership status at any time; however, administrative fees may be incurred.
Group registration is not available online and does not apply to the already-discounted fees for government or charitable nonprofit/academia. To take advantage of this offer, please download this registration form for EACH of the four registrants from your company. Include the names of all four group registrants on each of the forms and return them together to DIA.
Travel and Hotel
The most convenient airport is Ronald Reagan National Airport and attendees should make airline reservations as early as possible. The Washington Marriott Wardman Park Hotel is holding a block of rooms at the reduced rate below until January 25, 2012, for the DIA event attendees. Room availability at this rate is guaranteed only until this date or until the block is filled.
Single $229 Double $229
Attendees must make their own hotel reservations. Contact the Washington Marriott Wardman Park Hotel by telephone at 1.202.328.2000 or Toll-free within the US 1.800.228.9290 and mention the DIA event. The hotel is located at 2660 Woodley Road, NW, Washington, DC, 20008, USA.
Cancellation Policy
On or before February 8, 2012
Administrative fee that will be withheld from refund amount:
Member or Nonmember = $200
Government or Academia or Nonprofit (Member or Nonmember) = $100
Tutorial (if applicable) = $50
Cancellations must be in writing and be received by the cancellation date above. Registrants who do not cancel by that date and do not attend will be responsible for the full registration fee paid. Registrants are responsible for cancelling their own hotel and airline reservations. You may transfer your registration to a colleague at any time but membership is not transferable. Please notify DIA of any such substitutions as soon as possible. Substitute registrants will be responsible for nonmember fee, if applicable.
DIA reserves the right to alter the venue, if necessary. If an event is cancelled, DIA is not responsible for any airfare, hotel or other costs incurred by registrants.
Participants with Disabilities
DIA event facilities and overnight accommodations are accessible to persons with disabilities. Services will be made available to sensory-impaired persons attending the event if requested at least 15 days prior to event. Contact the DIA office to indicate your needs.
Exhibit Information
Fee
Tabletop…………………$1,500.00
Tabletop Rental Fee includes:
- One (1) 6' skirted table;
- One (1) chair;
- Standard electricity
Each Tabletop rental requires at least one registered attendee to staff the table. All tabletop staff is required to register as an attendee for the conference.
Exhibits Show Dates
February 16-17, 2012
Washington Marriott Wardman Park
Washington, DC, USA
DIA Exhibits Contact Information
Jeff Korn | Worldwide Exhibits Associate
Phone: 1.215.442.6184 | Jeff.Korn@diahome.org | Fax: 1.215.442.6199
Useful Links
Application for Tabletop Display